

P1483

Abstract (poster session)

In vitro activity of tigecycline against *Streptococcus pneumoniae* in the United States: TEST 2009-2010

S. Bouchillon*, S. Hawser, C. Zampaloni, M. Hackel, B. Johnson, D. Hoban, M. Dowzicky (Schaumburg, US; Epalinges, CH; Colleville, US)

Objectives: *S. pneumoniae* (SPN) continues to be recognized as a significant respiratory and bacteremia pathogen. Resistance to both oral and parenteral antibiotics used to treat SPN infection continues to evolve and newer antibiotics are needed with anti-SPN activity. The Tigecycline Evaluation and Surveillance Trial (TEST) is an ongoing global surveillance trial designed to follow trends in antimicrobial activity for tigecycline (TIG); amoxicillin-clavulanic acid (A/C); ceftriaxone (CAX); clindamycin (CLIN); erythromycin (ERY); levofloxacin (LVX); meropenem (MER); and penicillin (PEN). This report evaluates the in vitro activity of tigecycline and comparators against SPN in the United States (US) from 2009 - 2010. Methods: A total of 559 clinical isolates were collected from 78 cumulative investigator sites in the US. Clinical isolates were identified to the species level at each participating site and confirmed by the central laboratory with the Optichin disk test. Minimum Inhibitory Concentrations (MICs) were determined both by the local laboratory and supplemented by a central laboratory using broth microdilution panels and interpreted according to current CLSI and FDA (tigecycline) guidelines. Results: In vitro results are presented in the following table: - MIC90 not calculated for n's <10. * MDR - MultiDrug-Resistant (3 or more drug classes). Conclusions: TIG inhibited \geq 99% of all SPN at its FDA breakpoint of 0.06 mg/L for all SPN collected during the course of this study including Pen-, Levo-, Macro-Resistant, and MDR isolates. The in vitro activity of TIG was comparable to that of LVX.

Phenotype	N	MIC ₉₀ (mg/L)/% Susceptible							
		TIG	A/C	CAX	CLIN	ERY	LVX	MER	PEN
All SPN	559	0.03/99	8/84	2/89	>64/79	64/59	1/99	1/79	4/61
Pen-Res	104	0.03/99	8/23	2/46	>64/33	>64/13	1/98	2/3.9	4/0
Macro-Res	221	0.03/100	8/66	2/79	>64/46	>64/0	1/99	1/57	4/28
MDR*	86	0.03/100	>8/8.1	2/40	>64/15	>64/3.5	1/98	2/1.2	8/0